循环脂蛋白脂质与载脂蛋白同冠心病风险的关系:多变量孟德尔随机化分析
研究利用UK Biobank脂质全基因组关联数据与CARDIoGRAMplusC4D冠心病数据,行单变量和多变量孟德尔随机化,比较LDL胆固醇、甘油三酯、载脂蛋白B、HDL胆固醇和载脂蛋白A-I对冠心病风险的因果作用,发现载脂蛋白B是主要致病特征。
要点
- 单变量MR中LDL胆固醇、甘油三酯和载脂蛋白B均与冠心病风险升高相关。
- 多变量MR中仅载脂蛋白B保持稳健因果效应,LDL胆固醇效应逆转,甘油三酯效应减弱。
- HDL胆固醇和载脂蛋白A-I的保护效应在校正载脂蛋白B后大幅衰减至无效。
核心结论
- 载脂蛋白B是解释脂蛋白脂质与冠心病病因学关系的主要特征。
研究设计与样本
- 在UK Biobank进行脂质和载脂蛋白的全基因组关联研究,纳入393,193至441,016名个体,平均年龄56.9岁,54.2%为女性。
- 使用CARDIoGRAMplusC4D冠心病数据(60,801例病例和123,504例对照)进行单变量和多变量孟德尔随机化分析。
主要发现
- 单变量MR中,LDL胆固醇每升高1个标准差,冠心病OR为1.66(95%CI 1.49-1.86,P<0.001)。
- 单变量MR中,甘油三酯每升高1个标准差,冠心病OR为1.34(95%CI 1.25-1.44,P<0.001)。
- 单变量MR中,载脂蛋白B每升高1个标准差,冠心病OR为1.73(95%CI 1.56-1.91,P<0.001)。
- 多变量MR中,仅载脂蛋白B保持稳健效应,OR为1.92(95%CI 1.31-2.81,P<0.001)。
- 多变量MR中,LDL胆固醇OR为0.85(95%CI 0.57-1.27,P=0.44),甘油三酯OR为1.12(95%CI 1.02-1.23,P=0.01)。
关键数值与推荐
- 单变量MR中,HDL胆固醇每升高1个标准差,冠心病OR为0.80(95%CI 0.75-0.86,P<0.001)。
- 单变量MR中,载脂蛋白A-I每升高1个标准差,冠心病OR为0.83(95%CI 0.77-0.89,P<0.001)。
- HDL胆固醇和载脂蛋白A-I的效应估计在校正载脂蛋白B后大幅衰减至无效。
临床怎么用
- 载脂蛋白B可能是评估冠心病风险的优先脂蛋白相关指标。
- 针对载脂蛋白B的干预可能比单纯降低LDL胆固醇或甘油三酯更具病因学意义。
局限性
- 脂蛋白代谢特性导致脂蛋白颗粒组成相关指标高度相关,难以对单个成分的因果作用做出排他性解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating lipoprotein lipids cause coronary heart disease (CHD). However, the precise way in which one or more lipoprotein lipid-related entities account for this relationship remains unclear. Using genetic instruments for lipoprotein lipid traits implemented through multivariable Mendelian randomisation (MR), we sought to compare their causal roles in the aetiology of CHD. METHODS AND FINDINGS: We conducted a genome-wide association study (GWAS) of circulating non-fasted lipoprotein lipid traits in the UK Biobank (UKBB) for low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B to identify lipid-associated single nucleotide polymorphisms (SNPs). Using data from CARDIoGRAMplusC4D for CHD (consisting of 60,801 cases and 123,504 controls), we performed univariable and multivariable MR analyses. Similar GWAS and MR analyses were conducted for high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I. The GWAS of lipids and apolipoproteins in the UKBB included between 393,193 and 441,016 individuals in whom the mean age was 56.9 y (range 39-73 y) and of whom 54.2% were women. The mean (standard deviation) lipid concentrations were LDL cholesterol 3.57 (0.87) mmol/L and HDL cholesterol 1.45 (0.38) mmol/L, and the median triglycerides was 1.50 (IQR = 1.11) mmol/L. The mean (standard deviation) values for apolipoproteins B and A-I were 1.03 (0.24) g/L and 1.54 (0.27) g/L, respectively. The GWAS identified multiple independent SNPs associated at P < 5 × 10-8 for LDL cholesterol (220), apolipoprotein B (n = 255), triglycerides (440), HDL cholesterol (534), and apolipoprotein A-I (440). Between 56%-93% of SNPs identified for each lipid trait had not been previously reported in large-scale GWASs. Almost half (46%) of these SNPs were associated at P < 5 × 10-8 with more than one lipid-related trait. Assessed individually using MR, LDL cholesterol (odds ratio [OR] 1.66 per 1-standard-deviation-higher trait; 95% CI: 1.49-1.86; P < 0.001), triglycerides (OR 1.34; 95% CI: 1.25-1.44; P < 0.001) and apolipoprotein B (OR 1.73; 95% CI: 1.56-1.91; P < 0.001) had effect estimates consistent with a higher risk of CHD. In multivariable MR, only apolipoprotein B (OR 1.92; 95% CI: 1.31-2.81; P < 0.001) retained a robust effect, with the estimate for LDL cholesterol (OR 0.85; 95% CI: 0.57-1.27; P = 0.44) reversing and that of triglycerides (OR 1.12; 95% CI: 1.02-1.23; P = 0.01) becoming weaker. Individual MR analyses showed a 1-standard-deviation-higher HDL cholesterol (OR 0.80; 95% CI: 0.75-0.86; P < 0.001) and apolipoprotein A-I (OR 0.83; 95% CI: 0.77-0.89; P < 0.001) to lower the risk of CHD, but these effect estimates attenuated substantially to the null on accounting for apolipoprotein B. A limitation is that, owing to the nature of lipoprotein metabolism, measures related to the composition of lipoprotein particles are highly correlated, creating a challenge in making exclusive interpretations on causation of individual components. CONCLUSIONS: These findings suggest that apolipoprotein B is the predominant trait that accounts for the aetiological relationship of lipoprotein lipids with risk of CHD.
引用
- Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med. 2020. PMID: 32203549. doi:10.1371/journal.pmed.1003062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。